Pathak R, Goldberg SB, Canavan M, et al. - In patients with node-negative, early-stage non–small cell lung cancer (NSCLC), researchers examined if adjuvant chemotherapy is linked with survival with vs in those without high-risk clinicopathologic features. Using data from the National Cancer Database, they conducted a retrospective cohort study of 50,814 treatment-naive patients with a completely resected node-negative NSCLC. Observations revealed correlation of receiving adjuvant chemotherapy with a survival benefit if the tumor was larger than 3 to 4 cm and sublobar resection was performed, the tumor was larger than 4 to 5 cm and at least 1 high-risk pathologic feature was present, or the tumor was larger than 5 cm irrespective of high-risk pathologic features. Based on these observations, they emphasize simultaneously evaluating high-risk clinicopathologic characteristics, extent of resection, and tumor size when considering patients with early-stage NSCLC for adjuvant chemotherapy.